Maternal Marijuana Use and Fetal and Infant Outcome

Sponsor
Johns Hopkins University (Other)
Overall Status
Withdrawn
CT.gov ID
NCT04266314
Collaborator
National Institute on Drug Abuse (NIDA) (NIH)
0
1
22.2
0

Study Details

Study Description

Brief Summary

Marijuana and cannabis-containing products are growing in popularity and availability in the United States, and use during pregnancy has increased dramatically. The overarching aim of this proposal is to provide pilot data for a submission which will explore the impact of chronic maternal marijuana use (primary or secondary) on fetal functioning, maternal reflective functioning and infant birth and neurodevelopmental outcomes. Chronically marijuana using pregnant women in treatment at the Center for Addiction and Pregnancy will be enrolled and asked to provide information about participants' marijuana and other licit and illicit substance use and feelings about parenting and participants' infant and undergo fetal monitoring at 36 weeks gestation. The neonates will undergo neurobehavioral examination during the first and fourth weeks of life.

Condition or Disease Intervention/Treatment Phase
  • Device: Maternal-fetal monitoring
  • Other: NICU Network Neurobehavioral Scale

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Maternal Marijuana Use and Fetal and Infant Outcome
Actual Study Start Date :
Apr 10, 2019
Actual Primary Completion Date :
Feb 15, 2021
Actual Study Completion Date :
Feb 15, 2021

Outcome Measures

Primary Outcome Measures

  1. Change in Prevalence of maternal cannabis use disorder [The first day of study enrollment and again at infant delivery]

    Rates of Cannabis use disorder among pregnant women reporting primary or secondary (i.e. first or second drug of choice) cannabis use during pregnancy.

  2. Fetal functioning as assessed by fetal heart rate [One day during 36th weeks of gestation]

    Fetal heart rate in beats per minute will be measured.

  3. Fetal functioning as assessed by fetal movement [One day during 36th weeks of gestation]

    Fetal movement: number and length in msecs of bouts of fetal movement as determined by fetal actograph testing

  4. Change in infant neurobehavioral functioning as assessed by the NICU Network Neurobehavioral Scale [One day during week 1 and week 4 of infant life]

    Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale scores.

  5. Change in Maternal reflective functioning as assessed by the Parental Reflective Functioning Questionnaire [At 36 weeks of gestation, postpartum week 1, postpartum week 4]

    Responses that evaluate the mother's ability to reflect on and interpret her own behavior and that of her child in terms of mental states and intentions; this will be assessed using the Parental Reflective Functioning Questionnaire.

  6. Infant weight at birth [At the time of delivery]

    Birth weight in kilograms

  7. Infant length at birth [At the time of delivery]

    Infant length in centimeters

  8. Infant head circumference at birth [At the time of delivery]

    Infant head circumference in centimeters

  9. Infant Apgar Score at 1 minute [At 1 minute after delivery]

    Apgar Score after birth at one minute; scores range from 1-10 with higher scores signifying more optimal infant well being at birth.

  10. Infant Apgar Score at 5 minutes [At 5 minutes after delivery]

    Apgar Score after birth at five minutes; scores range from 1-10 with higher scores signifying more optimal infant well being at birth.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 44 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Maternal Inclusion Criteria:
  • Singleton pregnancy less than 36 weeks of gestation

  • Marijuana as a primary or secondary drug of choice

Maternal Exclusion Criteria:
  • Significant fetal anomaly

  • Multiple gestation

  • Delivery prior to 36 weeks gestation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Johns Hopkins Bayview Medical Center Baltimore Maryland United States 21224

Sponsors and Collaborators

  • Johns Hopkins University
  • National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Lauren Jansson, MD, Johns Hopkins University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT04266314
Other Study ID Numbers:
  • IRB00190055
First Posted:
Feb 12, 2020
Last Update Posted:
Feb 17, 2021
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Johns Hopkins University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 17, 2021